Matritech to benefit from European patent:
This article was originally published in Clinica
The European Patent Office has informed the Massachusetts Institute of Technology that it intends to grant a patent for the organisation's nuclear matrix proteins. The patent will cover Massachusetts-based Matritech's cancer-marking technology, which MIT licenses to the company. Matritech already has US patents for the technology and has applications pending in Canada and the Far East. The patent covers Matritech's NMP22 bladder cancer test kit which was launched outside the US in July (see Clinica No 662, p 19).
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.